| Product Name | Kim1 ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Kidney Injury Molecule 1 (Kim1). No significant cross-reactivity or interference between Kidney Injury Molecule 1 (Kim1) and analogues was observed. |
| Synonyms | HAVCR1; TIM1; TIMD1; HAVCR; Hepatitis A Virus Cellular Receptor 1; T Cell Immunoglobulin And Mucin Domain-Containing Protein 1; T-cell immunoglobulin mucin receptor 1 |
| Method | Sandwich |
| Detection Range | 78-5,000pg/mL |
| Sensitivity | 32pg/mL |
| Target | Kim1 |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Kidney Injury Molecule 1 (Kim1). No significant cross-reactivity or interference between Kidney Injury Molecule 1 (Kim1) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Tissue Homogenates, Urine, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | Q96D42 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Clinical implication of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in patients with acute paraquat intoxication;KIM-1 and NGAL: new markers of obstructive nephropathy;Urinary Neutrophil Gelatinase-Associated Lipocalin at Birth Predicts Early Renal Function in Very Low Birth Weight Infants;Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate;Interleukin 18 as a Marker of Chronic Nephropathy in Children after Anticancer Treatment;Kidney injury molecule-1: a urinary biomarker for contrast induced acute kidney injury.;Urinary neutrophil gelatinase-associated lipocalin predicts graft loss after acute kidney injury in kidney transplant;、118 ;Tubular urinary biomarkers do not identify aetiology of acute kidney injury in kidney transplant recipients;SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial;The diagnosis of febrile urinary tract infection in children may be facilitated by urinary biomarkers;Kidney injury molecule-1: A urinary biomarker for contrast-induced acute kidney injury;Role of new biomarkers for predicting renal scarring in vesicoureteral reflux: NGAL, KIM-1, and L-FABP;Urinary NGAL, KIM-1 and L-FABP concentrations in antenatal hydronephrosis;Kidney Injury Molecule Levels in Type 2 Diabetes Mellitus;Urinary Kidney Injury Molecule-1 but Not Urinary Neutrophil Gelatinase Associated Lipocalin Is Increased after Short Maximal Exercise;Urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, N-acetyl-β-D-glucosaminidase levels and mortality risk in septic patients with …;The Kidney Specific Protein myo-Inositol Oxygenase, a Potential Biomarker for Diabetic Nephropathy;Urine markers of renal tubular injury in idiopathic membranous nephropathy: A cross sectional study;Application of ELISA Technique and Human Microsomes in the Search for 11β-Hydroxysteroid Dehydrogenase Inhibitors;Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures;Can Serum Neutrophil Gelatinase Associated Lipocalin and Kidney Injury Molecule-1 Help in Decision Making for Surgery in Antenatally Dedected …;Rationale and design of the intervention in PHOspholamban RElated CArdiomyopathy STudy (i-PHORECAST);Early Kidney Injury in Immunoglobulin A Vasculitis: Role of Renal Biomarkers;Value of urinary kidney injury molecule-1 levels in predicting acute kidney injury in very low birth weight preterm infants;Could urinary kidney injury molecule-1 be a good marker in subclinical acute kidney injury in mild to moderate COVID-19 infection?; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEA785Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
